Literature DB >> 22658301

Treatment outcome of patients with stages I-II nasopharyngeal carcinoma after late course accelerated hyperfractionation radiotherapy alone.

Xiayun He1, Ming Ye2, Xiaomao Guo3, Ziqiang Pan1, Zhen Zhang1, Shaoqin He1, Taifu Liu1.   

Abstract

OBJECTIVES: To follow up the efficacy and incidence of radiation-induced complications of late course accelerated fractionation (LCAF) radiotherapy in early-stage nasopharyngeal carcinoma (NPC).
MATERIALS AND METHODS: From December 1995 to November 2002, 158 patients with stages I-II NPC were admitted for radiotherapy alone. For the first two-thirds of the treatment, 2 daily fractions of 1.2 Gy were given to the primary lesion, 5 days per week to a total dose of 48 Gy/40 fractions, over a period of 4 weeks. From the 5th week, an accelerated hyperfractionation schedule was carried out. Two daily fractions of 1.5 Gy were given, to a total dose of 30 Gy/20 fractions over 2 weeks. Thus the total dose was 78 Gy in 60 fractions in 6 weeks.
RESULTS: All patients completed the treatment. Acute mucositis: none in 3 patients, grade 1 in 32, grade 2 in 69, grade 3 in 51, and grade 4 in 3 patients. Five-year nasopharyngeal control and overall survival (OS) rate of T1 and T2 were 97.8%, 90.2% (p=0.380) and 88.6%, 81.4% (p=0.252), respectively. Five-year OS in N0 and N1 patients were 86.5% and 81.9% (p=0.033), respectively. Thirty-eight patients died, and the main cause of death was distant metastasis. Seventeen (11%) patients had radiation-induced cranial nerve palsy.
CONCLUSION: With LCAF, treatment-related toxicities were acceptable. Five-year nasopharyngeal control and OS in T2 stage were improved. Main cause of death was distant metastasis. Patients with N1 had a relatively lower survival rate, which suggested that chemotherapy might be indicated for those patients.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22658301     DOI: 10.1016/j.oraloncology.2012.05.008

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  5 in total

1.  Radiation-induced lower cranial nerve palsy in patients with head and neck carcinoma.

Authors:  Stefan Janssen; Christoph Glanzmann; Bita Yousefi; Karl Loewenich; Gerhard Huber; Stephan Schmid; Gabriela Studer
Journal:  Mol Clin Oncol       Date:  2015-05-04

Review 2.  Delayed lower cranial neuropathy after oropharyngeal intensity-modulated radiotherapy: A cohort analysis and literature review.

Authors:  Katherine A Hutcheson; Maggie Yuk; Rachel Hubbard; Gary B Gunn; C David Fuller; Stephen Y Lai; Heather Lin; Adam S Garden; David I Rosenthal; Ehab Y Hanna; Merrill S Kies; Jan S Lewin
Journal:  Head Neck       Date:  2017-04-28       Impact factor: 3.147

3.  Role of Chemotherapy in Stage II Nasopharyngeal Carcinoma Treated with Curative Radiotherapy.

Authors:  Min Kyu Kang; Dongryul Oh; Kwan Ho Cho; Sung Ho Moon; Hong-Gyun Wu; Dae-Seog Heo; Yong Chan Ahn; Keunchil Park; Hyo Jung Park; Jun Su Park; Ki Chang Keum; Jihye Cha; Jun Won Kim; Yeon-Sil Kim; Jin Hyoung Kang; Young-Taek Oh; Ji-Yoon Kim; Sung Hwan Kim; Jin-Hee Kim; Chang Geol Lee
Journal:  Cancer Res Treat       Date:  2015-02-13       Impact factor: 4.679

4.  Chemotherapy use and survival in stage II nasopharyngeal carcinoma.

Authors:  Xin-Bin Pan; Shi-Ting Huang; Kai-Hua Chen; Xiao-Dong Zhu
Journal:  Oncotarget       Date:  2017-10-11

5.  Predictive factors of chemotherapy use in stage II nasopharyngeal carcinoma: A retrospective cohort study.

Authors:  Xin-Bin Pan; Shi-Ting Huang; Kai-Hua Chen; Yan-Ming Jiang; Xiao-Dong Zhu
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.